InterMune stock rise ahead of meeting

The Pulmonary-Allergy Drugs Advisory Committee will meet tomorrow to discuss InterMune's idiopathic pulmonary fibrosis candidate pirfenidone, a product FDA staffers expressed concern about in briefing documents. FDA reviewers said only one of the company's two key trials showed efficacy, and "the clinical significance of the treatment effect size is uncertain." Despite the agency's concerns, investors who were braced for a more negative analysis sent the company's shares soaring Friday. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.